Rate of Epstein-Barr Virus in Gastric Adenocarcinoma in Egyptian Patients in View of the WHO Classification and Correlation with p16 Immunoreactivity
DOI:
https://doi.org/10.3889/oamjms.2022.9700Keywords:
Epstein-Barr virus, Gastric adenocarcinoma, qPCR, Immunohistochemistry, p16 proteinAbstract
BACKGROUND AND AIM: Gastric cancer (GC) is one of the top causes of cancer-related deaths worldwide. According to the Cancer Genome Atlas, there are four subtypes of GC, with the Epstein-Barr virus (EBV) subtype accounting for about 10% of cases. EBV infection causes EBV-associated GC (EBVaGC). The previous research suggested that the presence of the EBV viral genome in gastric carcinomas could be used as a surrogate marker for targeted therapy and optimal GC treatment.
AIM: We aimed to explore the rate of EBV involvement in gastric carcinogenesis from molecular perspective view and to evaluate the role of the tumor-suppressor protein p16 as a marker for diagnosis in GC Egyptian patients in relation to EBV infection.
METHODS: One hundred-four surgically resected GC cases were analyzed. Two methods including quantitative real-time polymerase chain reaction (qPCR) for detecting EBV-derived latent membrane protein-1 (LMP-1) and Epstein-Barr nuclear antigen-1 (EBNA-1) genes as well as immunohistochemistry (IHC) detection of LMP-1 protein and p16 protein on paraffinized tissue blocks were applied.
RESULTS: Using IHC, p16 protein was presented in 90/104 (86.5%) of the GC cases, and EBV LMP-1 was detected in 4 cases (3.84%). qPCR detected 14 cases positive for EBV (13.46%). In EBV positive cases detected using qPCR, no expression of p16 was detected.
CONCLUSION: EBVaGC has a low incidence in Egypt; loss of p16 expression was recognized in EBVaGC and could be considered as a promising biomarker of EBVaGC. The combination of the two methods IHC and qPCR in addition to p16 is recommended for improving the accuracy of identification of infected cancer.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Sun K, Jia K, Lv H, Wang SQ, Wu Y, Lei H, et al. EBV-positive gastric cancer: Current knowledge and future perspectives. Front Oncol. 2020;10:583463. https://doi.org/10.3389/fonc.2020.583463 PMid:33381453
American Cancer Society-Cancer Facts and Amp; Statistics. Georgia: American Cancer Society-Cancer Facts and amp; Statistics; 2020.
Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78. https://doi.org/10.1016/j.ejphar.2014.07.025 PMid:25058905
Siebenhüner AR, Dosso D, Winder T, Burg V, Borner M. Pederiva S, et al. Advanced gastric cancer: Current treatment landscape and a future outlook for sequential and personalized guide: Swiss expert statement article. 2021;44(9):485-94. https://doi.org/10.1159/000518107 PMid:34350899
Global Cancer Observatory. Source: Globocan 2020. Egypt: Global Cancer Observatory; 2020.
Cancer Rates in Egypt to Increase Three Times by 2050-Egypt Today; 2017.
Badawi H, El Said M, Samir S, Ismail A, Badawy A, Barakat A, et al. Prevalence of human papillomavirus genotypes among egyptian patients with cancer bladder. J Int Pharm Res. 2018;45:203.
Morales-Sánchez A, Fuentes-Pananá EM. Human viruses and cancer. Viruses. 2014;6(10):4047-79. https://doi.org/10.3390/v6104047 PMid:25341666
Camargo MC, Kim KM, Matsuo K, Torres J, Liao LM, Morgan DR, et al. Anti-helicobacter pylori antibody profiles in Epstein-barr virus (EBV)-positive and EBV-negative gastric cancer. Helicobacter. 2016;21(2):153-7. https://doi.org/10.1111/hel.12249 PMid:26251258
Osumi H, Kawachi H, Yoshio T, Ida S, Yamamoto N, Horiuchi Y, et al. Epstein-barr virus status is a promising biomarker for endoscopic resection in early gastric cancer: proposal of a novel therapeutic strategy. J Gastroenterol. 2019;54(9):774-83. https://doi.org/10.1007/s00535-019-01562-0 PMid:30826866
Garattini SK, Basile D, Cattaneo M, Fanotto V, Ongaro E, Bonotto M, et al. Molecular classifications of gastric cancers: Novel insights and possible future applications. World J Gastrointest Oncol. 2017;9(5):194-8. https://doi.org/10.4251/wjgo.v9.i5.194 PMid:28567184
Brasil-Costa I, de Souza CR, Costa IB, dos Santos LF, Paixão LC, Polaro AA, et al. Detection of Epstein-barr virus in gastric adenocarcinoma: qPCR and FISH comparison. Med Microbiol Immunol. 2022;211(1):29-36. https://doi.org/10.1007/s00430-021-00724-3 PMid:34862564
Zhao Y, Zhang J, Cheng AS, Yu J, To KF, Kang W. Gastric cancer: genome damaged by bugs. Oncogene. 2020;39(17):3427-42. https://doi.org/10.1038/s41388-020-1241-4 PMid:32123313
Liang C, Wu HM, Yu WM, Chen W. Research status on immunotherapy trials of gastric cancer. World J Clin Cases. 2021;9(21):5782-93. https://doi.org/10.12998/wjcc.v9.i21.5782 PMid:34368297
Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-9. https://doi.org/10.1038/nature13480 PMid:25079317
Fukayama M, Ushiku T. Epstein-barr virus-associated gastric carcinoma. Pathol Res Pract. 2011;207(9):529-37. https://doi.org/10.1016/j.prp.2011.07.004
Chen JN, He D, Tang F, Shao CK. Epstein-barr virus-associated gastric carcinoma: A newly defined entity. J Clini Gastroenterol. 2012;46(4):262-71. https://doi.org/10.1097/MCG.0b013e318249c4b8 PMid:22392024
Amoueian S, Attaranzadeh A, Gholamimoallem Z, Sadeghi M, Hashemi SM, Allahyari A. Epstein-barr virus infection in adult patients with gastric cancer in Northeast of Iran. Indian J Med Paediatr Oncol. 2018;39(2):206-209.
Mendaza S, Fernández-Irigoyen J, Santamaría E, Zudaire T, Guarch R, Guerrero-Setas D, et al. Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix. Int J Mol Sci. 2020;21(6):2125. https://doi.org/10.3390/ijms21062125 PMid:32204550
QI ZL, Han XQ, HU J, Wang GH, Gao JW, Wang X, et al. Comparison of three methods for the detection of Epstein-barr virus in Hodgkin’s lymphoma in paraffin-embedded tissues. Mol Med Rep. 2013;7(1):89-92. https://doi.org/10.3892/mmr.2012.1163 PMid:23128841
Ojima H, Saito K, Yamauchi H, Yamaki E, Idetu A, Hosouchi Y, et al. P16 protein abnormality in Epstein-barr virus-associated gastric carcinomas. Anticancer Res. 2006;26(2A):933-7. PMid:16619489
Konforte D, Simard N, Paige CJ. Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells. Virology. 2008;374(1):100-13. https://doi.org/10.1016/j.virol.2007.12.027 PMid:18222514
Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3(3):71-85. PMid:25558171
Xie T, Liu Y, Zhang Z, Zhang X, Gong J, Qi C, et al. Positive status of Epstein-barr virus as a biomarker for gastric cancer immunotherapy: A prospective observational study. J Immunother. 2020;43(4):139-44. https://doi.org/10.1097/CJI.0000000000000316 PMid:32134806
Evers DL, He J, Kim YH, Mason JT, O’Leary TJ. Paraffin embedding contributes to RNA aggregation, reduced RNA yield, and low RNA quality. J Mol Diagn. 2011;13(6):687-94. https://doi.org/10.1016/j.jmoldx.2011.06.007 PMid:21884819
Li J. Gastric cancer in young adults: A different clinical entity from carcinogenesis to prognosis. Gastroenterol Res Pract. 2020;2020:9512707. https://doi.org/10.1155/2020/9512707
Moore A, Hikri E, Goshen-Lago T, Barkan T, Morgenstern S, Brook E, et al. Young-onset gastric cancer and Epstein-Barr Virus (EBV)-A major player in the pathogenesis? BMC Cancer. 2020;20(1):34. https://doi.org/10.1186/s12885-020-6517-0 PMid:31937281
Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on epstein-barr virus and gastric cancer (review). Int J Oncol. 2015;46(4):1421-34. https://doi.org/10.3892/ijo.2015.2856 PMid:25633561
Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Mino-Kenudson M, et al. High levels of Epstein-barr virus DNA in latently infected gastric adenocarcinoma. Lab Invest. 2009;89(1):80-90. https://doi.org/10.1038/labinvest.2008.103 PMid:19002111
Tang W, Morgan DR, Meyers MO, Dominguez RL, Martinez E, Kakudo K, et al. Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile. Infect Agent Cancer. 2012;7(1):21. https://doi.org/10.1186/1750-9378-7-21 PMid:22929309
Zhang K, Wang H. Cancer genome Atlas pan-cancer analysis project. Zhongguo Fei Ai Za Zhi. 2015;18(4):219-23. https://doi.org/10.3779/j.issn.1009-3419.2015.04.02 PMid:25936886
Agrawal L, Engel KB, Greytak SR, Moore HM. Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Semin Cancer Biol. 2018;52(Pt 2):26-38. https://doi.org/10.1016/j.semcancer.2017.12.008 PMid:29258857
Shannon-Lowe C, Rowe M. Epstein barr virus entry; kissing and conjugation. Curr Opin Virol. 2014;4:78-84. https://doi.org/10.1016/j.coviro.2013.12.001 PMid:24553068
Caves EA, Butch RM, Cook SA, Wasil LR, Chen C, Di YP, et al. Latent membrane protein 1 is a novel determinant of Epstein-barr virus genome persistence and reactivation. mSphere. 2017;2(6):e00453-17. https://doi.org/10.1128/mSphereDirect.00453-17 PMid:29134204
Tsao SW, Tsang CM, Pang PS, Zhang G, Chen H, Lo KW. The biology of EBV infection in human epithelial cells. Semin Cancer Biol. 2012;22(2):137-43. https://doi.org/10.1016/j.semcancer.2012.02.004 PMid:22497025
Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-barr virus. Semin Cancer Biol. 2014;26:60-8. https://doi.org/10.1016/j.semcancer.2014.01.002 PMid:24457012
Woellmer A, Hammerschmidt W. Epstein-barr virus and host cell methylation: Regulation of latency, replication and virus reactivation. Curr Opin Virol. 2013;3(3)260-5. https://doi.org/10.1016/j.coviro.2013.03.005 PMid:23567077
Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M. Latent membrane protein 1 inhibits Epstein-barr virus lytic cycle induction and progress via different mechanisms. J Virol. 2003;77(8):5000-7. https://doi.org/10.1128/jvi.77.8.5000-5007.2003 PMid:12663807
Young LS, Rickinson AB. Epstein-barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757-68. https://doi.org/10.1038/nrc1452. PMid:15510157
Wang H, Wang J, Zhao B. Correlation of p16 and cyclin D1 expression with the incidence and prognosis of cardiac carcinoma. Oncol Lett. 2019;17(6):4859-64. https://doi.org/10.3892/ol.2019.10189 PMid:31186693
Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, et al. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol. 2002;160(3):787-94. https://doi.org/10.1016/S0002-9440(10)64901-2 PMid:11891177
Osawa T, Chong JM, Sudo M, Sakuma K, Uozaki H, Shibahara J, et al. Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma. Jpn J Cancer Res. 2002;93(11):1195-200. https://doi.org/10.1111/j.1349-7006.2002.tb01223.x PMid:12460459
Schneider BG, Gulley ML, Eagan P, Bravo JC, Mera R, Geradts J. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-barr virus and anatomic location in the body of the stomach. Hum Pathol. 2000;31(1):45-50. https://doi.org/10.1016/s0046-8177(00)80197-5. PMid:10665912
Downloads
Published
How to Cite
License
Copyright (c) 2022 Safia Samir, Hend Okasha Ahmed, Tarek M. Diab, Amr Mostafa, Hesham A. Elmeligy, Amira Kamel, Heba Khalil (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
